The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation by Veena Roberts et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 18 February 2014
doi: 10.3389/fimmu.2014.00064
The role of ectonucleotidases CD39 and CD73 and
adenosine signaling in solid organ transplantation
Veena Roberts1, John Stagg2 and Karen M. Dwyer 1*
1 Immunology Research Centre, St. Vincent’s Hospital Melbourne and Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia
2 Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, QC, Canada
Edited by:
Sophie Brouard, Centre National de la
Recherche Scientifique, France
Reviewed by:
Stanislaw Stepkowski, University of
Toledo, USA
Philippe Saas, Etablissement Français
du Sang BFC, France
*Correspondence:
Karen M. Dwyer , Immunology
Research Centre, St Vincent’s
Hospital, Level 1 Healy Wing, 41
Victoria Parade, Melbourne VIC 3065,
Australia
e-mail: karen.dwyer@svhm.org.au
Extracellular adenosine is a potent immunomodulatory molecule that accumulates in states
of inflammation. Nucleotides such as adenosine triphosphate and adenosine diphosphate
are release from injured and necrotic cells and hydrolyzed to adenosine monophosphate
and adenosine by the concerted action of the ectonucleotidases CD39 and CD73. Accumu-
lating evidence suggest that purinergic signaling is involved in the inflammatory response
that accompanies acute rejection and chronic allograft dysfunction. Modification of the
purinergic pathway has been shown to alter graft survival in a number of solid organ
transplant models and the response to ischemia–reperfusion injury (IRI). Furthermore, the
purinergic pathway is intrinsically involved in B and T cell biology and function. Although T
cells have traditionally been considered the orchestrators of acute allograft rejection, a role
for B cells in chronic allograft loss is being increasingly appreciated.This review focuses on
the role of the ectonucleotidases CD39 and CD73 and adenosine signaling in solid organ
transplantation including the effects on IRI and T and B cell biology.
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INTRODUCTION
Solid organ transplantation is life sustaining and the preferred
treatment for patients with end stage organ disease. Despite
improvements in short term graft survival coincident with more
potent immunosuppression, long term graft survival has not
changed significantly. Although, the cause of chronic allograft
dysfunction and failure has not been fully elucidated, evidence
implicates recurrent episodes of acute allograft rejection in the
pathogenesis. Life-long immunosuppression is a necessity in all
but a few patients and a delicate balance exists between sufficient
immunosuppressive to preserve graft integrity and unwanted side
effects consequent to excess exposure. Immunological tolerance
remains the panacea of transplantation medicine enabling long
term allograft survival with the avoidance of immunosuppression
toxicities.
A number of factors have been identified, which increase graft
immunogenicity and the risk of rejection. Vast immunological dis-
parity, evident in xenotransplantation, is a potent activator of the
recipient’s immune system inciting an immediate, aggressive, and
fulminant response termed hyperacute rejection (HAR). How-
ever, lesser antigen mismatches are also sufficient to trigger the
alloimmune response, which may be classified histopathologically
as cell mediated rejection (CMR) or antibody mediated rejection
(AMR). The phenomenon of ischemia–reperfusion injury (IRI),
an obligatory event in the transplantation process occurring at the
time of organ procurement and engraftment, increases the risk of
delayed graft function and immunogenicity of the graft particu-
larly in the setting of extended cold preservation times. Strategies
to curb the recipient’s immune response to such events without
escalating immunosuppressive requirements remain the focus of
intense research.
Current immunosuppressive regimens specifically target T cell
activation as a means of preventing allograft rejection. The success
of this approach is reflected in the exceptional 1 year graft survival
of transplanted organs. However, despite the improvements in
short term survival, long term graft survival remains static, and
these agents are far less efficacious in combating chronic rejection.
Recently, a role for B cells in chronic rejection has been appreci-
ated; however, B cells may also be beneficial to the graft (1). B cells
are able to modulate the T cell response by both enhancing the
primary T cell response and promoting regulatory T cell (Treg)
activity. These data have led researchers to conclude that func-
tionally distinct B cell subsets exist classified as B effectors and B
regulatory cells, respectively (2). The exact mechanisms by which
B cells exert regulatory function are as yet unknown but putatively
involve IL-10 which they produce (3).
Adenosine is an innate immunomodulatory molecule, the peri-
cellular concentration of which rises dramatically in states of
inflammation. Nucleotides such as adenosine triphosphate (ATP)
and adenosine diphosphate (ADP) are extruded from injured
and necrotic cells and hydrolyzed to adenosine monophosphate
(AMP) by the ectonucleotidase NTPDase family of which CD39
(NTPDase1) is the prototype. AMP is then hydrolyzed by the 5′
ectonucleotidase CD73 to adenosine (4). Adenosine signals via
four G protein coupled receptors namely A1,A2A,A2B, and A3. A1R
and A3R are coupled to the G-inhibitory subunit which leads to
a reduction in intracellular cAMP upon activation, whereas A2AR
and A2BR are coupled to the G-stimulatory subunit resulting in
an increase in intracellular cAMP. In addition, A2BR couples to Gq
proteins, which stimulate phospholipase C activity and intracel-
lular calcium mobilization (5). Originally described as a marker
of B cell activation (6), CD39 expression has been demonstrated
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on resting B cells (2), T cells including Treg (7, 8), neutrophils (9),
NK cells (10) monocytes, and macrophages (11). Similarly, CD73
was originally used as a surface marker to identify individual B
cell subsets at specific stages of differentiation (12), but has since
been demonstrated on resting B cells (2), T cells including Treg
(13), neutrophils (9), NK cells (14) monocytes, and macrophages
(11). CD39 and CD73 are co-expressed on resting B cells; however
CD73 is down-regulated with activation (2). The ability to generate
adenosine by these cells facilitates immunoglobulin diversification
via class switch recombination, an essential process in mounting
a humoral immune response (15) and which may impact graft
survival. Within the T cell population CD39 and CD73 are co-
expressed by Treg (8). Further, the adenosine receptor expression
pattern has been detailed on both cellular subsets. The A2AR is
expressed by T cells under basal conditions and is up regulated
following activation (8). Recently, the importance of the A2AR on
Treg function has been appreciated (16, 17). On B cells the A1, A2A,
and A3R are all expressed although signaling via the A3R inhibits
B cell proliferation (2).
There is mounting evidence that purinergic signaling is
involved in the inflammatory response that accompanies rejection
and in chronic allograft dysfunction. Modification of the puriner-
gic pathway has altered graft survival experimentally in a number
of solid organ transplant models and the response to IRI. Further-
more, the purinergic pathway is intrinsically involved in both B and
T cell biology, cell subsets critical in maintaining allograft survival.
This review focuses on the role of ectonucleotidases (NTP-
Dase1/CD39 and CD73) and adenosine signaling in solid organ
transplantation including the effects on IRI and impact on
lymphocyte biology.
CARDIAC TRANSPLANTATION
Chronic cardiac allograft rejection manifests as coronary allograft
vasculopathy (CAV), a rapidly progressive form of atherosclero-
sis that leads to reduced blood flow and ischemia and is a major
cause of death in patients surviving more than 1 year after heart
transplantation (18). Although numerous immune-mediated and
metabolic risk factors have been implicated in the pathogenesis
of CAV (19), to date no effective treatment is available to fully
eliminate CAV and its related adverse outcomes. The main thera-
peutic strategy against CAV is the prevention and treatment of the
factors known to trigger or accelerate the disease such as repeated
episodes of acute allograft rejection and prolonged cold ischemia
time associated with severe IRI.
CD39, CD73, AND A2BR MEDIATES PROTECTION IN CARDIAC
ISCHEMIA–REPERFUSION INJURY
CD39 is a ubiquitously expressed integral immune and vascular
ectonucleotidase and manipulation of this ectoenzyme is likely to
impact on graft rejection in which inflammation and coagulation
predominate. Indeed in the original description of mice defi-
cient in CD39, CD39−/− cardiac xenografts underwent rejection
with more rapid vascular occlusion than did the matched wild-
type (WT) murine hearts when grafted into rats (20). Throm-
botic and inflammatory immunopathological changes were more
evident in the mutant vasculature at earlier time-points com-
pared with WT donor hearts. Replacement of CD39 in the form
Table 1 | Expression of the ectonucleotidases and adenosine receptors
on the organ parenchyma during ischemia–reperfusion injury.
Organ parenchyma Ectonucleotidase and adenosine
receptors critical in IRI
Heart CD39, CD73, A2BR
Trachea (lung) A2AR
Liver CD39, CD73
Kidney CD39, CD73, A2BR
of adenovirus-mediated over-expression (21) or administration
of apyrase (22), a soluble form of CD39, prolonged cardiac
xenograft survival with reduced vascular thrombosis. Consistent
with this the transgenic over-expression of CD39 improved cardiac
xenograft survival with less platelet sequestration and preservation
of cardiac architecture histologically (23).
NTPDase biochemical activity initially falls dramatically in the
donor heart following transplantation but rebounds and CD39
mRNA expression is significantly increased in grafts that survive
long term (24). Both human and murine CD39 mRNA expression
has been documented to increase in a time dependent manner
under hypoxic conditions and is dependent on the transcrip-
tion factor Sp1 (25). Indeed, the phenomenon of ischemic pre-
conditioning (IP), which involves multiple sublethal episodes of
ischemia and reperfusion that augments adenosine concentrations
and protects against further ischemia, robustly increases CD39
expression on endothelia and myocytes (26) (Table 1). Precondi-
tioned WT hearts are significantly protected (26), whereas CD39
deficient hearts are more susceptible to myocardial infarction fol-
lowing coronary ischemia due to less ATP hydrolyzing ability
(25). Conversely, mice treated with apyrase (26) or over-expressing
CD39 (27) are protected against myocardial infarction following
coronary artery occlusion through A2BR dependent mechanisms
(27). These data implicate purinergic signaling pathways in the
innate response to cardiac hypoxia and transplantation.
The A2BR is critical in mediating cardioprotection against
hypoxic injury. Following 60 min of ischemia the area at risk was
significantly less in mice treated with the A2BR agonist BAY 60-
6583 (28) with the target gene being Per2, a circadian rhythm
protein that enhances the glycolytic capacity of the ischemic heart
through HIF-1α (29). The A2BR has been shown to increase post
cardiac transplantation as early as 4 h following engraftment and
parallels the changes in CD73 mRNA expression (14). Deficiency
of CD73 in either the donor or the recipient reduced graft sur-
vival and accelerated the development of CAV in a murine model
of cardiac transplantation and was associated with reduced A2BR
expression (14). These data suggest that the expression of CD73
and A2BR are coordinated and dependent under conditions of
cardiac hypoxia.
Cardiac transplantation involves a period of extended cold
preservation when the donor heart is stored on ice during
transportation to the recipient center. In a rat heterotopic heart
transplant model administration of an adenosine bolus before
cardioplegia and storage reduced myocardial injury and led to
faster reanimation following reperfusion. Grafts treated with
adenosine were less inflamed with fewer infiltrating cells (30).
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CD73 ACTIVITY LIMITS INNATE IMMUNITY FOLLOWING CARDIAC IRI
Bonner et al. (31) recently demonstrated that CD73 on circulating
immune cells was critical in cardiac healing in a model of cardiac
ischemia and reperfusion. Within 3 days of ischemia and reper-
fusion the myocardium was infiltrated with granulocytes and T
cells, which highly express CD73 (32). The generation of adeno-
sine was integral to limiting infarct size, inflammation, and the
development of fibrosis (31). Although infarct size and cardiac
ejection fraction were similar the day following ischemia, cardiac
function continued to deteriorate in CD73 deficient mice whereas
some recovery of function was observed WT mice. Lack of CD73
was associated with a sustained leukocytic myocardial infiltrate
of a Th1 and M1 phenotype with enhanced expression of TNFα,
IL-1β, IL-6, and IL-17 (31). Koeppen et al. (33) demonstrated
CD73-generated adenosine mitigated inflammation and fibrosis
preserving cardiac function through A2BR signaling specifically
on polymorphonuclear cells which limited the release of TNFα.
These data suggest that adenosine is critical in the response
of the heart to transplantation and augmenting peri-transplant
adenosine levels reduces the impact of IRI and improves graft
outcomes.
LUNG TRANSPLANTATION
Chronic pulmonary allograft dysfunction manifests as bronchi-
olitis obliterans syndrome (BOS), which is characterized by pro-
gressive airflow obstruction and deterioration in function. BOS
is a major complication following lung transplantation limit-
ing long term survival. Ischemia–reperfusion injury, acute rejec-
tion episodes, and CMV infection are independent predictors of
progressive BOS (34).
A2AR ACTIVATION ATTENUATES LUNG ISCHEMIA–REPERFUSION
INJURY
CD73 dependent generation of adenosine is essential in limit-
ing inflammation occurring early following lung transplantation.
Indeed greater inflammation was evident at 1 week in tracheal
allografts transplanted into CD73 deficient recipient mice (35).
The inflammatory infiltrate demonstrated increased CD3+ T cell
infiltration and was accompanied by greater expression of Th1
cytokines IFNγ and IL-2 resulting in luminal narrowing. In the WT
allografts, marked upregulation of A2AR mRNA expression was
evident such that treatment of CD73 deficient recipients with an
A2AR agonist rescued the allograft. In fact A2AR activation potently
attenuates lung IRI if given before ischemia (36) or during reper-
fusion (37). Inflammation and pulmonary edema were maximally
decreased and lung function optimized in a blood perfused rabbit-
lung model subjected to ischemia followed by treatment with the
specific A2AR agonist ATL313. When ischemia was combined with
an A2AR inhibitor, this effect was abolished (36). Furthermore,
cardiac dysfunction occurring concomitantly with pulmonary IRI
is attenuated with A2AR activation (38). In mice A2AR activa-
tion reduces CD4+ T cell and neutrophil infiltration with marked
reduction in inflammatory cytokines such as TNFα, IL-17, MCP-1,
MIP-1, and RANTES (39) significantly improving lung function.
Human lung transplantation includes a period of cold
preservation, which slows cellular metabolism limiting ischemic
injury however; extended cold storage times increase the
incidence of delayed graft function. A2AR activation decreases the
inflammatory response and preserves pulmonary function fol-
lowing cold preservation and transplantation. Using a porcine
transplant model, Reece et al. (37) demonstrated that treatment
of the recipient pig with A2AR agonist beginning 10 min prior
to and continuing for the first 3 h of reperfusion improved out-
come. In this model, the porcine lung was subjected to 6 h of
cold ischemia followed by 4 h of reperfusion. Animals treated with
the intravenous infusion of A2AR agonist ATL-146e had improved
oxygenation with preserved CO2 levels and acid–base balance. The
measured pulmonary artery pressures and pulmonary vascular
resistance were also lower in the A2AR agonist treated group. The
overall lung injury score was significantly less primarily due to less
pulmonary infiltration in the treatment group.
Human donor lungs may be perfused ex vivo with Steen Solu-
tion® in order to optimize pulmonary function prior to engraft-
ment. Based on the beneficial effect of A2AR activation in small
animal warm ischemia–reperfusion models, Emaminia et al. (40)
examined the effect of supplementing Steen Solution® with A2AR
agonist on pig explanted lungs which had been stored at 4°C for 5 h.
Treated lungs demonstrated less edema, improved oxygenation
index and mean airway pressure and lower levels of IFNγ, IL-1β,
IL-6, and IL-18 suggesting A2AR agonist supplementation may
further optimize lung function prior to transplantation. Indeed
using a xenograft model, Westall et al. (41) demonstrated that
genetically modified pig lungs lacking the αGal gene and express-
ing human complement regulatory proteins (CD55, CD59) and
CD39 performed better ex vivo following perfusion with human
blood. Lungs from genetically modified pigs demonstrated stable
pulmonary vascular resistance, better oxygenation, and survived
longer than WT lungs. Multiple potential factors may have con-
tributed to the improved outcome including a putative effect of
CD39 generated adenosine.
A2AR ACTIVATION ATTENUATES ACUTE ALLOGRAFT REJECTION IN THE
LUNG
Recurrent episodes of acute allograft rejection promote the devel-
opment of BOS. A2AR signaling is important in modifying the
alloimmune response: A2AR activation reduces skin allograft rejec-
tion (42) and improves survival and functional engraftment of
transplanted islets by inhibiting inflammatory islet damage in the
peri-transplant period (43). Complete MHC mismatched tracheal
allografts are rejected within 3 weeks manifesting with complete
lumen obliteration. The kinetics of rejection was accelerated in
A2ARKO mice with more inflammatory infiltrate comprising
macrophages, neutrophils, and CD3+ T cells and collagen depo-
sition. Conversely treatment of allograft recipients with A2AR
agonist resulted in less leukocytic infiltrate and delay in luminal
obliteration supporting an effect of A2AR activation in limiting
ischemia–reperfusion injury (44). Intriguingly, a role for A2BR
signaling has also been proposed in the development of BOS exper-
imentally. A2BRKO mice recipient of a MHC mismatched tracheal
allograft developed less severe BOS at 3 weeks (45). A greater num-
ber of FoxP3+ Tregs were present in the tracheal grafts in A2BRKO
mice as early as day 3 post-op with concomitant reduction in neu-
trophils and CD4+ T cells, suggesting that A2BR activation may
promote BOS via inhibiting Treg infiltration. The opposing effects
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of A2AR and A2BR signaling in tracheal transplantation may reflect
the cellular expression of each adenosine receptor; the affinity for
adenosine being approximately 50 times greater for the A2AR (ref)
and that in addition to signaling via the G-stimulatory subunit and
increasing intracellular cAMP, A2BR activation promotes calcium
mobilization (ref).
Together, these data demonstrate evidence for A2AR activa-
tion in limiting acute pulmonary IRI and reducing alloimmune
response with significant improvement in lung function following
transplantation. On the other hand, A2BR signaling may pro-
mote allograft dysfunction indicating early inhibition may be
therapeutically advantageous.
LIVER TRANSPLANTATION
CD39 AND A2BR ACTIVITY IS PROTECTIVE IN LIVER IRI
Liver transplantation remains the only therapeutic option for
patients with end stage liver failure. The prevention of early graft
dysfunction principally due to IRI is critical as there are lim-
ited supportive options available. As in other solid organs hepatic
IP potently induces the transcription of CD39 via Sp1 (46) and
CD73 (47), which promotes local adenosine generation protect-
ing against subsequent prolonged ischemia. CD39 deficient (48)
and CD73 deficient (47) mice are unable to be preconditioned and
remain highly susceptible to the effects of prolonged ischemia with
high mortality due to significant hepatic infarction.
Hypoxic preconditioning, like IP, confers protection against
subsequent liver ischemia with marked attenuation of serum ALT,
TNF-α, and IL-6 (49). This technique involves breathing 10%
oxygen for 10 min prior to prolonged ischemia and results in
a doubling of plasma adenosine concentrations. Employed in
A2BRKO mice or inhibition of the A2BR negated the protective
effect of hypoxic preconditioning providing the first evidence for
the A2BR pathway in the prevention of warm hepatic IRI (49).
Deceased-donor and living-donor split-liver transplantation is
a technique used to increase organ utility amongst potential recip-
ients. The liver has a remarkable ability to regenerate after injury
or resection and liver growth occurs at a rapid pace (50). CD39
plays a critical role in the regenerative capacity of the liver and
is significantly attenuated in CD39 deficient mice (51). Stem cell
mobilization directly correlates with restoration of liver volume
and function and this is impaired in mice chimeric with CD39
deficient bone marrow (52).
A2AR ACTIVATION AND CD39 ACTIVITY REDUCES HEPATIC
INFLAMMATION POST IRI
Inflammation is an innate response to hepatic ischemia and reper-
fusion and T cells rapidly accumulate within the liver parenchyma.
Administration of A2AR agonist during reperfusion significantly
reduces liver injury following a period of ischemia, an effect lost
in A2ARKO mice (53). Through a series of studies using chimeric
mice, it was determined that it was the activation of the A2AR on
circulating cells that conferred protection with less liver injury,
reduced neutrophil infiltration, and induction of proinflamma-
tory cytokine transcripts (54). These data were further refined by
Lappas et al. (55), who demonstrated that the NKT cell subset of
CD4+ T cells principally mediated early liver injury. Following
72 min of liver ischemia and 2 h of reperfusion CD1d-dependent
activation of NKT cells lead to an increase in IFN-γ expression.
Injury could be recapitulated in RAG-1 KO mice through the trans-
fer of NKT cells and treatment of these cells prior to transfer with
an A2AR agonist mitigated injury (55). However, activation of NKT
cells prior to the ischemic insult actually confers protection. Cao
et al. (56) activated NKT cells 1 h prior to ischemia and showed a
reduction in neutrophilic infiltration and injury, which was both
IL-13 and A2AR dependent.
Although these data implicate a pathogenic role for NKT cells in
warm hepatic IRI this is not the case with cold IRI. Using a murine
liver transplant model where the recipient mouse had undergone
a total hepatectomy and was transplanted with either a donor liver
from a WT or CD39 over-expressing mouse that had been stored at
4°C for 18 h, Pommey et al. showed significant protection in donor
livers from CD39 over-expressing mice (57). In a series of chimeric
studies and through detailed immunophenotyping of CD39 over-
expressing mice the protective effect was attributed to a decrease
in resident hepatic CD4+ T cells and the effect could be replicated
through depletion of CD4+ T cells in WT mice. Notably, mice
deficient in NKT cells remained susceptible to the effects of cold
IRI. These data indicate significant differences in the pathogenetic
mechanisms underlying warm and cold IRI associated with liver
transplantation.
RENAL TRANSPLANTATION
Renal transplantation remains the optimal form of renal replace-
ment therapy for patients with end stage renal disease. Similar to
other solid organ transplants long term survival is limited by the
development of chronic allograft dysfunction which in the kidney
manifests with interstitial fibrosis and tubular atrophy. Risk fac-
tors for late allograft loss include acute rejection that is increased in
patients with delayed graft function and which in turn is impacted
by IRI particularly with prolonged cold preservation times.
Evidence for the CD39-adenosinergic axis in renal IRI has
been appreciated for some time and was recently reviewed (58).
CD39 transcript expression is upregulated with IP (59) and CD39
deficient mice are highly susceptible to injury (60). Mice that over-
express CD39 (61) or pre-treated with apyrase (59) are robustly
protected from injury which is A2BR dependent (unpublished
Karen M. Dwyer). As with other solid organs a period of cold
ischemia often occurs in renal transplantation. Crikis et al. (61)
examined the effect of CD39 over-expression in the donor kid-
ney following a period of 5 h at 4°C. The donor kidney was
transplanted into a bilaterally nephrectomized mouse recipient,
which was culled 24 h later. Recipients receiving the CD39 over-
expressing graft had better renal function as reflected by lower
serum creatinine correlating with less tubular injury in the graft.
These mice also remained healthy with preserved renal function up
to 3 days post transplantation as opposed to mice receiving the WT
kidney that did not survive to day 3 post renal transplantation (61).
Like CD39, CD73 is essential for preconditioning prior to renal
ischemia (62). Intriguingly, Rajakumar et al. (63) described pro-
tection against injury in CD73 deficient mice. In this model, mice
underwent 18 min of ischemia followed by 24 h of reperfusion,
which induced mild injury in WT mice. Nevertheless, CD73KO
mice were protected from injury and a similar result was obtained
when WT mice were pre-treated with a CD73 inhibitor. These data
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FIGURE 1 | Protective mechanisms in solid organ transplantation.
Extracellular adenosine is generated from the enzymatic hydrolysis of
nucleotides by the ectoenzymes CD39 and CD73 expressed on
endothelial cells (EC) and B cells. Adenosine signals via A2AR on
circulating cells including regulatory T cells (Treg) and via A2BR expressed
both on the vasculature and inflammatory cells. Experimental strategies
which improve graft outcome for each solid organ transplant are listed in
boxes.
implicate direct biological activity of AMP, which has recently been
ascribed in vitro at the A1R (64).
With respect to adenosine signaling, A2AR activation mitigates
inflammation inherent in this injury and parenchymal A2BR sig-
naling improves post ischemic blood flow limiting injury (65, 66).
CD4+ T cells are critical in mediating renal injury and pretreat-
ment of mice with A2AR agonist significantly lessens this burden
(67). As demonstrated in liver IRI, the CD4+ subset of NKT cells
are activated rapidly after renal IRI, which is followed by the activa-
tion of other immune cells (68). Blocking dendritic cell mediated
NKT cell activation via A2AR agonist treatment markedly reduced
renal injury (69). Indeed, inhibition of adenosine receptor signal-
ing is required for optimal dendritic cell, and subsequent T cell,
activation (70). A series of elegant studies by Kinsey et al. (16, 17,
71) have emphasized the role of Tregs in inhibiting CD4+ T cell
effector function through upregulation of PD-1 expression, which
is augmented by A2AR activation.
Regulatory T cells traditionally have been defined by CD4
and CD25 co-expression and the transcription factor FoxP3.
This subset have also been shown to express CD39 (7, 8, 72)
and CD73 (8, 13) and the A2AR (8, 17). CD39 is essential for
the full suppressive capabilities of these cells and mice defi-
cient in CD39 are immunocompromised being more suscep-
tible to T cell mediated diabetes (73) and experience more
rapid skin graft rejection (8). In humans CD4, CD25, and
CD39 expression identifies four T cell subsets, which can be fol-
lowed longitudinally in the peripheral blood of renal transplant
recipients (72).
SUMMARY
The process of solid organ transplantation involves ischemia–
reperfusion injury that promotes immunogenicity of the donor
organ leading to an increased risk of rejection and graft loss.
Although T cells have been traditionally considered the orches-
trators of these pathological processes, a role for B cells is being
increasingly recognized. The recent identification and character-
ization of B cell subtypes; the recognition of dual but opposing
effects on T cells; the putative involvement in allograft rejection
make these cells a potentially attractive therapeutic target.
The ectonucleotidases CD39 and CD73 are involved in adeno-
sine generation and expressed by these important immune cell
subsets. Adenosine signaling is integral to the function of both
B and T cells, is protective in warm and cold ischemic injury
and has immunomodulating properties, see Figure 1. There are
current adenosine receptor agonists and antagonists being tested
[reviewed in Ref. (74)] in non-transplant human trials but the
ubiquitous nature of adenosine receptors make targeted therapy
difficult. Potentially treatment of the donor organ prior to implan-
tation with adenosine receptor agonists may reduce the impact of
ischemia–reperfusion injury, subsequent acute rejection and graft
failure.
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